A. Hjelm Skog

Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery

L. Grimelius, G. Lundell, G. Wallin, 2002, British Journal of Cancer.

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma

J. Fagerberg, J. Shetye, B. Nilsson, 1999, Cancer Immunology, Immunotherapy.

Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2.

M. Wadhwa, C. Bird, R. Thorpe, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

A. Höög, E. Edström Elder, B. Hamberger, 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A

H. Mellstedt, B. Nilsson, P. Ragnhammar, 2003, International journal of cancer.

MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.

Jan Fagerberg, J. Fagerberg, H. Mellstedt, 2002, Hybridoma and hybridomics.